For Immediate Release
Tanner Pharma Group
SEATTLE, WA – The Max Foundation (“Max”), an international health organization dedicated to serving cancer patients, and Tanner Pharma Group (“Tanner”), a global pharma services company specializing in access to critical medication, are committed partners in bringing thousands of patients around the globe daily access to cancer treatment. Within The Max Foundation’s patient-centered model, Max Access Solutions (MAS), Tanner plays a critical role by leading quality, regulatory and logistics to ensure donated oncology products get to the right patient in the right place at the right time. MAS programs currently deliver 1,000,000 daily doses per Quarter.
Among the dozens of countries The Max Foundation supports, many are located in Africa. To raise awareness and funds for increased treatment access on the continent, Max has created a 2018 campaign known as the Max Global Experience: Uganda.
This campaign is focused on the proverbial “last mile,” which refers to the unseen efforts of patients and caregivers to make treatment truly accessible. All too often, patients must travel great distances to attend medical appointments and receive their medication. Max works to bridge these gaps by broadening its geographic reach, working with local patient groups, advocating to governments, and partnering with distribution experts like Tanner. Tanner has proudly offered to be the title sponsor for the Max Global Experience: Uganda and their parent company, Bourne Partners, will match up to $10,000 in funds raised.
“As we work to find solutions for patients in need, we feel fortunate to partner with a trusted Managed Access Program provider like Tanner Pharma Group,” said Pat Garcia-Gonzalez, CEO and co-founder of The Max Foundation. “We are strongly aligned in our values around the importance of access to cancer treatment for people around the world. As a result, we have forged a successful partnership in our Max Access Solution model which provides life-saving medication to patients in more than 70 countries. We look forward to growing our programs with Tanner and improving the lives of more cancer patients in under-resourced countries.”
“We are proud of our affiliation with The Max Foundation and the support we provide for their innovative, globally recognized programs,” added Banks Bourne, Founder & Chairman of Tanner Pharma Group and CEO of Bourne Partners. “Working with Pat and her team is deeply rewarding. Their hard work has led to monumental impact at the patient level.”
In 2017, Mr. Bourne attended another Max Global Experience, this time climbing Mt. Kinabalu in Malaysia. Banks recalls, “Seeing their work in Asia last summer and looking ahead to the upcoming trip to Africa has been inspirational and makes Tanner’s mission even more meaningful.”
About The Max Foundation
The Max Foundation is a global health organization that believes all people living with cancer deserve access to the best treatment, care, and support. The company works to decrease premature mortality from cancer by channeling humanitarian donations of life-saving oncology products to underserved populations in countries where those products are not locally available. For more information, visit www.themaxfoundation.org.
About Tanner Pharma Group
Tanner Pharma Group partners with biopharmaceutical companies and NGOs to provide turn-key solutions that facilitate access to medicines around the world. Every member of the Tanner Team believes that access to medicines should have no borders and we measure our value as a company based on the lives we improve. For more information, visit www.tannerpharma.com.
About Tanner Pharma Group
For over 15 years, Tanner’s executive team has provided specialty distribution of pharmaceuticals from markets of availability to markets of need. When healthcare providers in international markets require treatments not currently available in their home market, they rely on Tanner to source and deliver the product from its global network of pharmaceutical manufacturers. Based on its track record of accountability and experience managing regulatory-compliant access programs, top pharmaceutical and biotech companies partner with Tanner to develop and manage their global access programs. By partnering with Tanner, pharma and biotech companies are able to focus on their primary markets while ensuring that patients in international markets of need are receiving their products through a strictly controlled channel.
Tanner’s International Access Division serves providers in 24 of the most challenging countries by developing, implementing and managing global access programs including Named Patient Programs, Expanded Access Programs, Compassionate Use Programs, Government & Private Provider Tender fulfillment and Emergency Supply allocations. Tanner’s Clinical Trials Division procures comparator products for manufacturers, CRO’s and research centers from a broad range of sources. Additionally, the company is able to provide clinical trial logistics and inventory management for trials conducted in the U.S., Europe, Mexico and Brazil.
Headquartered in the U.S., Tanner’s reach includes Europe, Northeast Asia, Southeast Asia, the Middle East, Australia, Canada and Latin America, including Brazil, Mexico, the Caribbean, Central America and all of South America.
For more information about Tanner Pharma Group, please visit www.tannerpharma.com.
For more information about Merz or the Company’s products, please visit www.merzusa.com.